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Abstract
Background: Investigations into the regulation and functional roles of kinases such as cAMP-dependent protein kinase
(PKA) increasingly rely on cellular assays. Currently, there are a number of bioluminescence-based assays, for example
reporter gene assays, that allow the study of the regulation, activity, and functional effects of PKA in the cellular context.
Additionally there are continuing efforts to engineer improved biosensors that are capable of detecting real-time PKA
signaling dynamics in cells. These cell-based assays are often utilized to test the involvement of PKA-dependent processes
by using H-89, a reversible competitive inhibitor of PKA.
Principal Findings: We present here data to show that H-89, in addition to being a competitive PKA inhibitor, attenuates
the bioluminescence signal produced by Renilla luciferase (RLuc) variants in a population of cells and also in single cells.
Using 10 mM of luciferase substrate and 10 mM H-89, we observed that the signal from RLuc and RLuc8, an eight-point
mutation variant of RLuc, in cells was reduced to 50% (615%) and 54% (614%) of controls exposed to the vehicle alone,
respectively. In vitro, we showed that H-89 decreased the RLuc8 bioluminescence signal but did not compete with
coelenterazine-h for the RLuc8 active site, and also did not affect the activity of Firefly luciferase. By contrast, another
competitive inhibitor of PKA, KT5720, did not affect the activity of RLuc8.
Significance: The identification and characterization of the adverse effect of H-89 on RLuc signal will help deconvolute data
previously generated from RLuc-based assays looking at the functional effects of PKA signaling. In addition, for the current
application and future development of bioluminscence assays, KT5720 is identified as a more suitable PKA inhibitor to be
used in conjunction with RLuc-based assays. These principal findings also provide an important lesson to fully consider all of
the potential effects of experimental conditions on a cell-based assay readout before drawing conclusions from the data.
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Introduction
Protein kinases control many intracellular signaling cascades by
enzymatically transferring the c-phosphate of ATP to amino acid
side chains of protein targets. Aberrant signal transduction, such as
dysregulation of protein kinases, can result in pathophysiological
states [1]. As many signal transduction cascades have shared
molecular components, it is fundamentally important to study
protein kinases in cells where the entire signaling network remains
intact [2]. Many cell-based assays have focused on determining the
dependence of a specific cellular effect on a given kinase over a set
period of time [3–5]. More recently, however, there have been
efforts to design biosensors which are capable of monitoring
signaling dynamics in real-time [5–8]. These newer tools have the
potential to elucidate the dynamic series of molecular interactions
and modifications that contribute to a specific cellular effect.
Together, the application of current and the development of new
cell-based assays for kinase activity will continue to provide
insights regarding the connection between the regulation and
dynamics of kinase activity and a given functional response.
Cyclic AMP-dependent protein kinase (PKA), one of the first
discovered protein kinases, is well characterized [9]. PKA plays a
role in, among other things, transcriptional control of genes
downstream of the cAMP response element (CRE) [10],
maintenance and control of several metabolic processes, rear-
rangement of actin for muscle contraction and relaxation [11], and
DNA replication [12]. It is also implicated in a number of diseases
such as Alzheimer’s disease [13], cancer [14], heart disease [15],
and diabetes [16]. Consequently, PKA remains one of the most
frequently studied protein kinases [9]. One commonly used
technique that serves to monitor the functional effects of PKA in
cells is bioluminescence. Bioluminescence is an endogenous
characteristic of many organisms in which an enzyme (luciferase)
oxidizes a substrate (luciferin) and emits photons. Scientists
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variety of bioassays suited for studies in vitro, in cell-based assays,
and in vivo. Bioluminescence-based assays are desirable because
they provide a low background, are simple to use, and are non-
destructive when used in living systems [4,6].
The most frequently used luciferase enzymes in bioassays are
from the firefly Photinus pyralis (FLuc) and the sea pansy Renilla
reniformis (RLuc). FLuc is 62kDa, ATP-dependent, and emits light
at 560nm, whereas RLuc is 36kDa, ATP-independent, and emits
at 480nm [5]. These different properties often determine for which
type of assay each luciferase would be better suited [3]. A common
application of these proteins is for reporter gene assays that detect
levels of transcription in a cell. In this case, the cDNA for the
luciferase is fused downstream of a given response element. In
response to various stimulations, the response element is activated
to a level which correlates with the amount of luciferase, and thus
the signal, produced. A common control for these reporter gene
assays is to have a spectrally distinct reporter gene under the
control of a highly active promoter to serve as a transfection
control or as a control for cell viability. Therefore FLuc and RLuc
are commonly used concurrently in reporter gene assays to test the
dependence of specific stimuli on transcription levels in cells.
In addition to reporter gene assays, bioluminescence proteins
are being used in the design of biosensors that can capture
signaling dynamics in living cells. Such live-cell tools have been
developed to detect protein-protein interactions, second messenger
dynamics, enzyme (namely protease and kinase) activity, and
receptor activation by utilizing techniques such as luciferase
complementation assays, bioluminescence resonance energy
transfer (BRET), and circular permutation of luciferases, [6–8].
When developing such assays to specifically monitor kinase
activity, PKA often serves as a prototype for the design of new
biosensors.
Cellular bioluminescence-based assays provide readout for a
specific cellular event such as gene transcription. Testing the
dependence of a specific cellular response on a molecule of interest
is achieved via pharmacological stimulation or inhibition of a
protein of interest. In the case of PKA, commonly used activators
are agonists of the b-adrenergic receptors or activators of adenylyl
cyclases, both of which are upstream activators of PKA. To inhibit
PKA activity in cells, the reversible and competitive inhibitor of
PKA, H-89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline-
sulfonamide) is most commonly used [17]. Generally, stimulation
or inhibition of a protein of interest provides direct evidence
regarding the protein’s role in the cellular process under study.
Sometimes, however, it is possible that an agent that is added to
the experiment to inhibit a specific target is actually directly
modulating the activity of the luciferase.
We encountered this scenario while characterizing a novel cell-
based assay to detect PKA activity using a more stable and
brighter version of RLuc (RLuc8) [18] as the reporting unit. Upon
addition of H-89 to cells, we noticed a rapid, significant decrease
in RLuc8 signal in our PKA-independent negative control
(unpublished), and we thus suspected that the decrease in RLuc8
signal was not due to PKA inhibition alone. We further
investigated the nature of the decrease in RLuc8 signal and
showed that H-89 was responsible for the attenuation of the
bioluminescence signal.
Results
We hypothesized that there were two possibilities for the
decrease in RLuc8 signal after addition of H-89: PKA modulates
RLuc8 activity in such a way that PKA inhibition decreases the
signal from RLuc8, or H-89 directly attenuates the signal
produced by RLuc8. In order to test the possibility that H-89
directly attenuated the RLuc8 bioluminescence signal while
avoiding the complication of PKA-dependent inhibition of RLuc8,
we expressed RLuc8 in HEK293T cells along with the PKA
peptide inhibitor (PKIa) [19], as this would ensure that PKA was
inactive [20,21]. With PKA inhibited, we could directly monitor
the activity of RLuc8 independent of any PKA effect. The
transfected cells were plated into 96-well plates and allowed to
touch down for 24 hours. After a ten minute incubation with
concentrations of H-89 ranging from 0.5–100 mM, total light
output was measured. In this cellular context with PKA inhibited
by PKIa, after immediate addition of coelenterazine-h (a substrate
for luciferases from the Renilla family) we noticed that the signal
from RLuc8 decreased at concentrations of H-89 as low as
0.5 mM. Notably, at 10 mM H-89, the concentration used in most
cell-based studies to inhibit PKA activity, the RLuc8 signal was
reduced to 54% (614%) of control receiving vehicle alone
(Fig. 1A). In cells expressing RLuc8 with active PKA, in other
words without overexpression of PKIa, a similar decrease in signal
was observed (Fig. S1). Together, these data suggested that H-89,
and not PKA, was responsible for abating the bioluminescence
signal produced by RLuc8 oxidation of coelenterazine-h.
To confirm that H-89 was responsible for the reduction in
bioluminescence signal, we tested the effect of H-89 on RLuc8 in
vitro. Purified RLuc8 was added to each well of a 96-well plate at
1 nM and incubated in Hank’s balanced salt solution (HBSS)
supplemented with concentrations of H-89 ranging from 0.1–
100 mM for 10 minutes. Coelenterazine-h was then added over a
range of concentrations from 0.1–50 mM and signal was detected
immediately after addition. By plotting the rate of coelenterazine-h
oxidation (normalized emission) versus concentration of coelenter-
azine-h, it was evident that increasing concentrations of H-89
decreased the maximal velocity (Vmax) of the reaction, suggesting
both that H-89 does not compete with coelenterazine-h in the
RLuc8 active site, and that the signal cannot be restored by adding
more coelenterazine-h to the reaction (Fig. 1B). Importantly, at
10 mM coelenterazine-h, a commonly used concentration of
substrate for Renilla luciferases, the IC50 of H-89 on RLuc8 is
21.0 mM( 64.0 mM) which is just twice the most commonly used
dose in cell-based assays for inhibition of PKA. Therefore, using
the most common doses of coelenterazine-h and H-89 in an
RLuc8-based assay for PKA will result in a significant reduction in
RLuc8 signal that could be wrongfully attributed to a decrease in
PKA activity.
Since RLuc8 is a relatively new variant of RLuc, and because
most current bioassays utilizing Renilla luciferases are based on
RLuc, we wanted to test the effect of H-89 on RLuc in cells. Thus
we co-expressed RLuc and PKIa in HEK293T cells and detected
bioluminescence in a multi-well format. After a 10 minute
preincubation with H-89, we observed that H-89 decreased the
signal of RLuc in a similar fashion to RLuc8. Specifically, with
10 mM H-89, RLuc signal was abated to 51% (615%) of control
receiving vehicle alone (Fig. 1C), and we observed a similar
pattern of RLuc signal attenuation in cells that expressed RLuc
without PKIa (Fig. S2). The effect of H-89 on both RLuc8 and
RLuc has two significant implications. First, H-89 should be used
with caution in RLuc- or RLuc8-based assays or alternative
inhibitors or assays should be used. Secondly any data previously
generated from such assays may have an element of bias.
In order to study the functional dependence of PKA in a given
cellular system, it is important to have a reversible inhibitor of
PKA that can be used in cells. For this reason, and for the purpose
of our studies, we wanted to find a reversible PKA inhibitor that
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tested the activity of RLuc8 in the presence of the small molecule
PKA inhibitor KT5720 [22]. Again, we transfected RLuc8 and
PKIa into HEK293T cells. In a multi-well format, we allowed the
cells to preincubate for 20 minutes with the reversible PKA
inhibitor KT5720 with concentrations ranging from 0.1–10 mMa s
this spans those commonly used in cell based-assays [23]. After
addition of coelenterazine-h, we observed that KT5720 did not
modulate RLuc8 activity across the tested range of concentrations
(Fig. 2). Thus, KT5720 can be used as an alternative to H-89 to
inhibit PKA activity in RLuc8-based bioassays.
Similarly, we wanted to test the effect of H-89 on FLuc activity.
Since FLuc and RLuc are not homologous we predicted that H-89
would not necessarily be an inhibitor of FLuc. Also, if H-89 did
not inhibit FLuc activity, FLuc would be suitable for use in
luciferase-based PKA assays. In a 96-well plate, 1 nM purified
FLuc was preincubated with H-89 over the same range of
concentrations, 0.5–100 mM, which we used in previous experi-
ments. Luminescence was recorded immediately after D-luciferin
(the substrate for FLuc) addition and it was found that H-89
showed no decrease in FLuc signal in vitro (Fig. 3); it was also
shown that FLuc activity was not reduced by 10 mM KT5720 (Fig.
S3). Therefore, FLuc can be used in the presence of H-89 or
KT5720 and would be suitable as a readout for PKA bioassays.
Cell-based assays offer the advantage of detecting single-cell
behaviors and at the same time present the challenge of dealing
with cell-cell variations. To confirm the inhibitory effects of H-89
on RLuc variants obtained with populations of cells in the plate-
reader format and characterize cell-cell variations, we imaged cells
expressing RLuc8 and PKIa on a microscope. Coelenterazine-h
was added to cells and allowed to incubate for 10 minutes. Images
were acquired at 4 minute intervals from a population of seven
cells until a two-point steady baseline was achieved. Then, 5 mM
H-89 was added to the imaging dish resulting in an initial decrease
in RLuc8 signal. After 10 minutes, the RLuc8 signal was reduced
to 51% (617%) of the maximal value, consistent with that
obtained from the larger population of cells in the multi-well
format (Fig. S4). Over another 25 minute period two additional
doses of H-89 decreased the RLuc8 emission to 20% (610%) of
peak intensity (Fig. 4). This data shows that though the inhibition
of RLuc8 by H-89 takes a period of 20 minutes to achieve
maximal inhibition, the effects of inhibition can be seen
immediately after addition. Thus, a decrease in luciferase signal
Figure 1. H-89 decreases the bioluminescence signal produced
by RLuc variants. (A) In a 96-well plate, HEK293T cells expressing
RLuc8 and PKIa were preincubated for 10 minutes with various doses of
H-89 (n=4 for each dose of H-89). 10 mM coelenterazine-h was added
to each sample and luminescence was detected immediately after
addition. **: p,0.005 (compared to DMSO). (B) 1 nM RLuc8 was
preincubated for 10 minutes over a range of concentrations of H-89
(n=3 for each dose of H-89) and luminescence was detected
immediately after coelenterazine-h addition. (C) In a 96-well plate,
HEK293T cells expressing RLuc and PKIa were preincubated for
10 minutes with various doses of H-89 (n=3 for each dose of H-89).
After addition of 10 mM coelenterazine-h, luminescence was detected
immediately. * p,0.05, ** p,0.005.
doi:10.1371/journal.pone.0005642.g001
Figure 2. KT5720 does not reduce the bioluminescence signal
from RLuc8 in cells. In a 96-well plate, HEK293T cells expressing
RLuc8 and PKIa were preincubated with KT5720 (n=3 for each dose of
KT5720). No reduction of signal was observed immediately after
addition of 10 mM coelenterazine-h.
doi:10.1371/journal.pone.0005642.g002
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A more substantial reduction of signal, however, will be observed
in assays that use longer H-89 incubation periods.
The single cell luciferase experiments provide two other key
observations. First, it is clear by looking at the initial images (t=15)
that the cells have a normal appearance, demonstrating that
overexpression of neither Rluc8 nor PKIa is toxic to the cells
(Fig. 4B). Further, since there are no morphological changes to the
cells during the imaging timeframe, the attenuation of biolumi-
nescence signal upon H-89 addition cannot be attributed to a cell
shape change.
Discussion
Protein kinases serve as the primary regulators of signal
transduction cascades by phosphorylating protein targets in
response to various extracellular and intracellular stimuli. In turn,
this phosphorylation contributes to the propagation of the signal
until a desired physiological response is generated. PKA is an
example of a ubiquitously expressed protein kinase that is involved
in a plethora of vital cellular functions. Elucidation of many of the
functional roles of PKA in regulating various cellular processes
relies on bioluminescence-based cellular assays. However, we
present evidence that H-89, a commonly used PKA inhibitor, can
directly decrease the bioluminescence signal resulting from RLuc
activity.
Though there are a few examples of small molecules that act as
inhibitors of FLuc reported in literature [24–26], one group at the
NIH Chemical Genomics Center hypothesized that often times
such molecules are overlooked. After performing a quantitative
high throughput screen of over 70,000 compounds, they identified
2311 inhibitors for FLuc. Many of these inhibitors were shown to
be competitive inhibitors of FLuc and the activity could be fully
restored by increasing the concentration of luciferin or ATP [27].
Most of these same compounds, however, were not potent
inhibitors of RLuc activity, likely because RLuc is an ATP-
independent enzyme. Though there has been an effort to identify
classes of drugs with common structures that act as luciferase
inhibitors, it remains important to fully characterize the effect of
experimental conditions on the luciferase while utilizing or
developing bioluminescence assays. In a recent example, incom-
plete understanding of the direct effect of a small molecule on a
reporter protein led to miss-interpretation of data from a cell-
based FLuc assay [28].
Since the mechanism of coelenterazine oxidation by RLuc is not
entirely understood, it is difficult to speculate on a mechanism of
H-89-induced attenuation of RLuc signal. However, it is known
that RLuc shares a conserved catalytic triad and 42% identity with
bacterial haloalkane dehalogenases of the LinB family [29]. These
proteins utilize the characteristic a/b hydrolase motif to
catalytically hydrolyze carbon-halogen bonds [30]. Therefore,
we considered the possibility that H-89, a brominated small
molecule, could bind to RLuc and induce a conformational
change in the enzyme that slows down the oxidation of
coelenterazine-h. However, in this case, a brominated small
molecule would bind to the RLuc active site and display
Figure 3. H-89 does not abate the bioluminescence signal
produced by FLuc in vitro. 1 nM FLuc was preincubated with
various doses H-89 (n=4 for each dose of H-89). After D-luciferin
addition, reduction in signal was not observed with any of the
treatments.
doi:10.1371/journal.pone.0005642.g003
Figure 4. H-89 reduces the signal from RLuc8 in single cells. HEK293T cells (n=7) expressing RLuc8 and PKIa were imaged in the presence of
10 mM coelenterazine-h. (A) After addition of 5 mM H-89, RLuc8 signal decreases. Additional doses of H-89 decrease the signal further. (B) Channel
intensity images (top) and pseudocolor images (bottom) of cells corresponding to (A) at t=15 min (before H-89 addition) and t=50 min (when signal
has reached maximum inhibition).
doi:10.1371/journal.pone.0005642.g004
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tively, H-89 may interact with coelenterazine-h and affect its
properties. Indeed, we observed that the presence of H-89 caused
a change in the fluorescence spectrum of coelenterazine-h in buffer
(Fig. S5), suggesting some interactions between these two
molecules, although no covalent adduct was observed via mass
spectrometry (Fig. S6).
Here we present evidence that the PKA inhibitor H-89
attenuates the bioluminescence signal produced by RLuc variants
both in cells and in vitro. This is an important piece of information
which serves two purposes. First, it can help deconvolute data
previously generated from RLuc-based assays that looked at PKA-
dependent cellular processes as it is likely that the interpretation of
such data was inadvertently distorted if H-89 was used. Second,
this data will guide the application of current RLuc-based assays
for PKA activity and also the development of new biolumines-
cence-based kinase biosensors. Specifically, we suggest that when
utilizing or developing RLuc-based assays for PKA activity, H-89
not be used to test the dependence of the assay on PKA as the data
would be unintentionally skewed. As an alternative to H-89, one
could use the reversible PKA inhibitor KT5720 or the irreversible
peptide inhibitor PKIa, to test the involvement of PKA.
Additionally, H-89 can be used in FLuc-based cellular assays
without the concern of a non-specific decrease in signal. Overall,
this data provides an important lesson to characterize all of the
potential effects of the experimental conditions on cell-based assays
with proper controls before drawing conclusions from data.
Otherwise, a compound or condition that specifically modulates
the activity of the reporting unit and not the event under study
could influence the interpretation of data.
Materials and Methods
Gene construction and protein purification
RLuc8, RLuc, and PKIa were PCR amplified and ligated into
pCDNA3 (Invitrogen) for mammalian expression and RLuc8 was
ligated into pRSETB (Invitrogen) for bacterial expression. RLuc8
in PRSETB was transformed into BL21(DE3) E. coli cells. A single
colony was grown to an O.D.600 of 0.6 and induced with 0.1 mM
IPTG. Cells were grown 12 hours at 37uC, spun at 10,000g for
10 min, and then lysed by sonication in lysis buffer (50 mM Tris–
HCl, pH 7.4, 300 mM NaCl, 0.2% Triton X-100, and protease
inhibitor cocktail (Roche)). Lysed cells were spun at 15,000 rpm
for 20 minutes and 100 mL of Ni-NTA beads (Qiagen) was added
to the supernatant. The protein/bead mixture was added to a
column with a polyethylene disc (Kontes) used as the filter. The
column was washed twice in buffer containing 50 mM Tris–HCl,
pH 7.4, 300 mM NaCl, and 10 mM imidazole, and then protein
was eluted off of the beads via an elution buffer containing
100 mM imidazole. Protein concentration was determined by
BCA assay (Thermo Scientific).
HEK293T-based assays
HEK293T were grown in DMEM cell culture media (Gibco)
supplemented with 10% FBS at 37uC with 5% CO2. Cells were
transfected via calcium phosphate at 60% confluency with RLuc8
or RLuc and PKIa. For plate reader studies, after a 24 hour
transfection period, cells were plated at 150,000 cells/well into
white-walled, clear- bottom 96 well plates (Corning) coated with
0.1mg/ml poly-D-lysine. After 24 hours, media was replaced with
HBSS supplemented with H-89 (Sigma) or KT5720 (Sigma).
Benzyl-coelenterazine (Nanolight Technology) was added to a
final concentration of 10 mM and luminescence readings were
recorded immediately. For imaging, cells were transfected directly
into 35 mm imaging dishes and imaged 24 hours later.
In vitro assays
1 nM RLuc8 or 1 nM FLuc (Promega) was added to white-
walled, clear- bottom 96 well plates in HBSS. H-89 was added
directly to wells and incubated at 4uC for 10 minutes. Luciferase
substrate (Benzyl-coelenterazine for RLuc8 or D-luciferin for
FLuc) was added to a final concentration of 10 mM and
luminescence was recorded immediately.
Plate reader luminescence detection
All luminescence readings were obtained on a FLUOstar
OPTIMA microplate reader without an emission filter.
Bioluminescence imaging and analysis
Cells were imaged on a Zeiss Axiovert 200M microscope with a
Hamamatsu ImagEM cooled charge-coupled device camera
controlled by METAFLUOR software (Universal Imaging,
Downingtown, PA). Using a 475DF40 emission filter and
450DRLP dichroic mirror, images were acquired immediately
after coelenterazine-h addition. Acquisition time was 30 seconds
and images were acquired every 2–4 minutes. H-89 was added
directly to the imaging dish. Images were background corrected
and processed on Image J software.
Supporting Information
Figure S1 H-89 attenuates the activity of RLuc8 in cells. RLuc8
was transfected into HEK293T cells and cells were plated in a
multiwell format. 24 hours later, cells were pre-incubated with H-
89 for 10 minutes. Luminescence was detected immediately after
addition of 10 mM coelenterazine-h. H-89 attenuated the activity
of RLuc8 in a dose-dependent manner (n=3). (** p,0.01
compared to DMSO).
Found at: doi:10.1371/journal.pone.0005642.s001 (0.04 MB TIF)
Figure S2 H-89 attenuates the activity of RLuc in cells. RLuc
was transfected into HEK293T cells. In a multiwell format, cells
were pre-incubated with H-89 for 10 minutes. Luminescence was
detected immediately after addition of 10 mM coelenterazine-h.
H-89 attenuated the activity of RLuc in a dose-dependent manner
(n=3). (** p,0.01 compared to DMSO)
Found at: doi:10.1371/journal.pone.0005642.s002 (0.04 MB TIF)
Figure S3 KT5720 does not attenuate FLuc activity in vitro.
10 nM FLuc was pre-incubated with 10 mM KT5720 for 10min.
Immediately after D-luciferin addition, there was no attenuation of
FLuc activity (n=5).
Found at: doi:10.1371/journal.pone.0005642.s003 (0.03 MB TIF)
Figure S4 Time course of vehicle and H-89 treatments from a
population of cells. HEK293T cells expressing RLuc8 and PKIa
were incubated in HBSS supplemented with 10 mM coelenter-
azine-h for 10 minutes and then were treated with 5 mM H-89 or
vehicle. There was a rapid, initial decrease in signal upon H-89
addition. Subsequent doses of H-89 further decrease the signal.
The signal from the vehicle control cells also decreases due to a
combined effect of enzymatic coelenterazine-h oxidation and
product (coelenteramide) inhibition of RLuc8. The study supple-
ments that of the single cell experiments (n=3).
Found at: doi:10.1371/journal.pone.0005642.s004 (0.04 MB TIF)
Figure S5 H-89 shifts the emission spectrum of coelenterazine-h.
The emission spectra of 10 mM coelenterazine-h in HBSS excited
H-89 Attenuates RLuc Signal
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changes the emission spectrum.
Found at: doi:10.1371/journal.pone.0005642.s005 (0.03 MB TIF)
Figure S6 H-89 and coelenterazine-h do not form a covalent
adduct. All samples were diluted in 50% ACN, 0.1% FA, loaded
into electrospray needle, sprayed at 900 V, and detected from m/z
between 350–1200. A) spectra of H-89. B) Spectra of coelenter-
azine-h. C) spectra of 1:1, H-89:coelenterazine-h
Found at: doi:10.1371/journal.pone.0005642.s006 (0.04 MB TIF)
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